Memantine Biogaran (Memantine Hydrochloride)

Memantine Biogaran is used within the Alzheimer’s disease therapeutic pathway to address cognitive decline in patients with moderate to severe disease.

• Alzheimer’s disease (moderate to severe): helps improve cognition, daily functioning, and overall clinical status in affected adults.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantine Biogaran may be associated with a range of adverse reactions.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: temporary disorientation.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe rash or skin reactions: including Stevens‑Johnson syndrome.
• Hepatic dysfunction: signs of liver injury.
• Suicidal ideation: thoughts of self‑harm.

Before initiating therapy, clinicians should consider several safety factors.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant NMDA antagonists: avoid combined use to prevent additive neuro‑toxicity.
• History of seizures: assess risk and monitor closely.
• Cardiovascular disease: monitor blood pressure and heart rate.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neuro‑toxicity.
• CNS depressants (e.g., benzodiazepines): may enhance sedation.
• High‑dose antihypertensives: risk of excessive blood pressure reduction.

Moderate Interactions (Monitor Closely)

• Acetylcholinesterase inhibitors (e.g., donepezil): may affect overall cognitive response.
• Diuretics: monitor electrolyte balance.
• Drugs cleared renally (e.g., metformin): adjust dosing if renal function declines.